General description
Breast cancer type 1 susceptibility protein (BCRA1; RING finger protein 53) functions as a tumor suppressor. BRCA1 is an important member of the DNA repair pathway. After DNA damage, BRCA1 is phosphorylated on multiple serine residues by the ATR kinase or Chk2, and is localized to lesion sites with PCNA. BRCA1 interacts with a wide range of proteins including Rad50, NBS1, and Mre11, c-Abl tyrosine kinase, and γH2A.X, involved in the detection of damaged DNA and activation of appropriate repair pathways. BRCA1 may also respond to DNA damage by promoting gene expression through association with transcriptional proteins and RNA polymerase II, and may regulate the p53 pathway by this mechanism. Previous studies have indicated that mutations in the BRCA1 gene may contribute to the development of breast and ovarian cancer.
~220 kDa and ~85 kDa observed. Multiple isoforms exist at various molecular weights and may be subject to post-translational modification.
Immunogen
Epitope: N-terminus
Recombinant protein corresponding to the N-terminus of human BRCA1.
Application
Anti-BRCA1 Antibody, clone MS110 is an antibody against BRCA1 for use in Western Blotting, ICC.
Immunocytochemistry Analysis: A 1:500 dilution of this antibody detected in BRCA1 in MCF7 cells.
Immunoprecipitation Analysis: A representative lot from an independent laboratory immunoprecipitated BRCA1 in IP (Wilson, C. A., et al. (1999). Nat Genet. 21(2):236-240.).
Immunohistochemistry Analysis: A representative lot from an independent laboratory detected BRCA in ovarian cancer and breast cancer tissues (Scully, R., et al. (1996). Science. 272(5258):123-126; Wilson, C. A., et al. (1999). Nat Genet. 21(2):236-240.).
Immunofluorescence Analysis: A representative lot from an independent laboratory detected BRCA1 in a variety of certain cell lines (Scully, R., et al. (1996). Science. 272(5258):123-126.).
Research Category
Apoptosis & Cancer
Research Sub Category
Cell Cycle, DNA Replication & Repair
Biochem/physiol Actions
This antibody recognizes the N-terminus of BRCA1.
Physical form
Format: Purified
Protein G Purified
Purified mouse monoclonal IgG1κ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.
Preparation Note
Stable for 1 year at 2-8°C from date of receipt.
Analysis Note
Control
HeLa nuclear extract
Evaluated by Western Blot in HeLa nuclear extract.
Western Blot Analysis: 1 µg/mL of this antibody detected BRCA1 in 10 µg of HeLa nuclear extract.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
| biological source | mouse |
| Quality Segment | 100 |
| conjugate | unconjugated |
| antibody form | purified immunoglobulin |
| antibody product type | primary antibodies |
| clone | MS110, monoclonal |
| species reactivity | human |
| technique(s) | immunocytochemistry: suitable,western blot: suitable |
| isotype | IgG1κ |
| NCBI accession no. | NP_009225 |
| UniProt accession no. | P38398 |
| shipped in | wet ice |
| target post-translational modification | unmodified |
| Gene Information | human ... BRCA1(672) |
